CHICAGO--(BUSINESS WIRE)--Fitch Ratings has assigned an 'A+' to Pfizer Inc.'s (Pfizer's) senior unsecured notes offering, which will be used to exchange Hospira's 2017, 2020, 2023 and 2040 senior unsecured notes. The Rating Outlook is Stable. A full list of ratings follows at the end of this press release. KEY RATING DRIVERS Acquisition Builds Existing Portfolio: The $17 billion acquisition of Hospira adds to Pfizer's global established pharmaceutical (GEP) business, particularly in the area of
| < Prev | Next > |
|---|
